Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 7, 2022 - Puma Biotechnology Presents Updated Findings from the TBCRC-022 trial at the 2022 San Antonio Breast Cancer Symposium Read
- Dec. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Nov. 3, 2022 - Puma Biotechnology Reports Third Quarter 2022 Financial Results - Raises FY 2022 NERLYNX Net Product Revenue Guidance Read
- Nov. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Oct. 27, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium Read
- Oct. 20, 2022 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
- Oct. 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 20, 2022 - Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor Read
- Sept. 11, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 Read
- Sept. 6, 2022 - Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference Read
- Sept. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 4, 2022 - Puma Biotechnology Reports Second Quarter 2022 Financial Results Read
- July 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
- July 6, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 7, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 6, 2022 - Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT trial at the ASCO 2022 Annual Meeting Read
- June 4, 2022 - Puma Biotechnology Presents Final Results from the Biliary tract Cohort of the Phase 2 SUMMIT ‘Basket’ trial of Neratinib at the ASCO 2022 Annual Meeting Read
- May 26, 2022 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting Read
- May 11, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- May 5, 2022 - Puma Biotechnology Reports First Quarter 2022 Financial Results Read
- April 27, 2022 - Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Read
- April 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
- April 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 10, 2022 - Puma Biotechnology Announces $10 Million Private Placement Read
- March 7, 2022 - Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Read
- March 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 3, 2022 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
- February 16, 2022 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Result Read
- February 3, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- January 20, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- January 12, 2022 - Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the treatment of Breast Cancer Read
- January 10, 2022 - Puma Biotechnology Releases Updated Corporate Presentation Read
- January 4, 2022 - Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference Read